Lastly, the existence of this novel KRAS-EHMT2 pathway that is critical for mediating the growth-promoting and immunoregulatory effects of this oncogene in vivo predicts that these therapies will likely impact both the tumor-initiating epithelial cells and the tumor microenvironment. Here, KRAS is linked to neoplasm.